{
    "clinical_study": {
        "@rank": "15006", 
        "arm_group": [
            {
                "arm_group_label": "ganaxolone", 
                "arm_group_type": "Experimental", 
                "description": "active"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo, non-active"
            }
        ], 
        "brief_summary": {
            "textblock": "The study will evaluate the effectiveness and safety of an investigational drug-ganaxolone -\n      on partial seizure frequency in adults with epilepsy taking a maximum of 3 antiepileptic\n      medications (AEDs)."
        }, 
        "brief_title": "Phase 2 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures, With Long-term Open-label Extension", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Drug Resistant Partial Onset Seizure", 
        "condition_browse": {
            "mesh_term": "Seizures"
        }, 
        "detailed_description": {
            "textblock": "This is a 67-week study comprised of a 4-week prospective baseline period plus 4 week\n      retrospective baseline followed by two treatment phases: a 9-week randomized DB\n      placebo-controlled treatment phase followed by a 52-week open label (OL) treatment phase. A\n      final safety assessment will be conducted two weeks following the end of the OL treatment\n      phase."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Able to give informed consent in writing, or have a legally authorized representative\n             able to do so\n\n          -  Willing to enter and participate for the full term of the double blind phase and\n             willing to enter into the open-label phase\n\n          -  Male or female outpatients > 18 years of age\n\n          -  Have a confident diagnosis of drug-resistant epilepsy with partial-onset seizures\n             (POS), with or without secondary generalization, for \u22652 years. Have residual POS\n             despite having been treated in the past with at least 2 approved anti-epilepsy drugs\n             (AEDs) either alone or in combination\n\n          -  Based on history, subjects would be anticipated to have at least 3 POS during each\n             4-week Baseline period and unlikely to have 21 or more consecutive POS-free days\n\n          -  Currently being treated and maintained with a stable regimen of 1, 2, or 3 AEDs\n\n          -  Able and willing to maintain daily seizure calendar\n\n          -  Able and willing to take drug with food twice daily\n\n          -  Sexually active women of childbearing potential must use acceptable birth control and\n             have a negative pregnancy test at all visits\n\n        Exclusion Criteria:\n\n          -  Have had previous exposure to ganaxolone\n\n          -  Known sensitivity or allergy to any component in the study drug, progesterone, or\n             other related steroid compounds\n\n          -  Exposure to any investigational drug or device < 30 days prior to screening, or plans\n             to take another investigational drug at any time during the study\n\n          -  Time of onset of epilepsy treatment < 2 years prior to enrollment\n\n          -  Have generalized epilepsy, such as Lennox-Gastaut syndrome, juvenile myoclonic\n             epilepsy, absence epilepsy, or non-epileptic seizures within the last 12- month\n             period prior to study entry\n\n          -  Have less than 3 POS seizures in a 28-day period  or more than 21 consecutive\n             seizure-free days during the Baseline period\n\n          -  Have only simple partial seizures without any observable motor component\n\n          -  Have innumerable seizures or status epilepticus within the last 12-months prior to\n             screening\n\n          -  Have more than 100 POS per 4-week Baseline period\n\n          -  Have seizures secondary to illicit drug or alcohol use, infection, neoplasm,\n             demyelinating disease, degenerative neurological disease, or central nervous system\n             (CNS) disease deemed progressive, metabolic illness, or progressive degenerative\n             disease\n\n          -  Current use of vigabatrin is not permitted. If prior use of vigabatrin, must have\n             documented stable visual fields\n\n          -  Current use of ezogabine is not permitted. If prior use, must have been off the\n             medication for at least 3 months prior to screening and have had documented normal\n             fundoscopic exam by ophthalmologist\n\n          -  Are planning surgery, or to be evaluated for surgery, during the double blind phase\n             to control seizures including VNS implantation\n\n          -  Are suffering from acute or progressive neurological disease, moderate or severe\n             psychiatric disease, or severe mental abnormalities that are likely to require\n             changes in drug therapy during the double blind portion of the study or interfere\n             with the objectives of the study or the ability to adhere to the protocol\n             requirements\n\n          -  Have a history of an actual suicide attempt in the last 5 years or more than 1\n             lifetime suicide attempt\n\n          -  Have a positive urine drug screen at Screening or meet criteria for current or\n             historical Substance Use Disorder (DSM-V criteria) within the past 5 years.\n\n          -  Have any medical condition that, in the investigator's judgment, is considered to be\n             clinically significant and could potentially affect subject safety or study outcome,\n             including but not limited to: clinically significant cardiac, renal, pulmonary,\n             gastrointestinal, hematologic or hepatic conditions; or a condition that affects the\n             absorption, distribution, metabolism or excretion of drugs\n\n          -  Have elevated ALT (SGPT) or AST (SGOT) greater than 3 times upper limits of normal,\n             or total bilirubin greater than 1.5 time ULN\n\n          -  Have a history of malignancy within the past 2 years, with the exception of basal\n             cell carcinoma\n\n          -  Are currently following or planning to follow a ketogenic diet\n\n          -  Use of dietary supplements or herbal preparations are not permitted if subject has\n             been using them consistently for less than 6 months prior to screening, or does not\n             plan on remaining on stable doses for the duration of the double blind phase. Use of\n             St. John's Wort is not permitted\n\n          -  Females who are pregnant, currently breastfeeding or planning to become pregnant\n             during the duration of the study\n\n          -  A history of chronic noncompliance with drug regimens\n\n          -  Inability to withhold grapefruit and grapefruit juice from diet during the entire\n             clinical trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01963208", 
            "org_study_id": "1042-0603"
        }, 
        "intervention": [
            {
                "arm_group_label": "ganaxolone", 
                "description": "200 mg and 225 mg capsules 2x/day", 
                "intervention_name": "ganaxolone", 
                "intervention_type": "Drug", 
                "other_name": "gnx"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "pbo"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "partial onset seizures", 
            "complex partial seizures", 
            "simple partial seizures", 
            "anticonvulsant", 
            "ganaxolone", 
            "neurosteroid", 
            "Marinus", 
            "epilepsy"
        ], 
        "lastchanged_date": "March 24, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Chall@uab.edu", 
                    "last_name": "Cheryl R Hall, CCRC", 
                    "phone": "205-934-1654"
                }, 
                "contact_backup": {
                    "last_name": "Jennifer DeWolfe, MD", 
                    "phone": "205-934-1654"
                }, 
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294-3280"
                    }, 
                    "name": "University of Alabama Epilepsy Center"
                }, 
                "investigator": {
                    "last_name": "Jennifer DeWolfe, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "neurophillip@yahoo.com", 
                    "last_name": "Phillip Escamilla", 
                    "phone": "559-437-9700"
                }, 
                "contact_backup": {
                    "last_name": "Perminder Bhatia, MD", 
                    "phone": "559-437-9700"
                }, 
                "facility": {
                    "address": {
                        "city": "Fresno", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93710"
                    }, 
                    "name": "Neuro-Pain Medical Center, Inc"
                }, 
                "investigator": {
                    "last_name": "Perminder Bhatia, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "eespinosa@drkudrow.com", 
                    "last_name": "Erica Espinosa", 
                    "phone": "310-315-1456"
                }, 
                "contact_backup": {
                    "email": "jlatorre@drkudrow.com", 
                    "last_name": "Jaime Latorre", 
                    "phone": "310-315-1456"
                }, 
                "facility": {
                    "address": {
                        "city": "Santa Monica", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90404"
                    }, 
                    "name": "Neurological Research Institute"
                }, 
                "investigator": {
                    "last_name": "David Kudrow, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kristen.lervik@ucdenver.edu", 
                    "last_name": "Kristen Lervik", 
                    "phone": "303-724-7309"
                }, 
                "contact_backup": {
                    "last_name": "Laura Strom, MD", 
                    "phone": "303.724.7309"
                }, 
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "University of Colorado- Anschutz Outpatient Pavilion"
                }, 
                "investigator": {
                    "last_name": "Laura Strom, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mvasconcelos@medsolcrc.com", 
                    "last_name": "Maria Vasconcelos", 
                    "phone": "941-623-9744"
                }, 
                "contact_backup": {
                    "email": "scoldiron@medsolcrc.com", 
                    "last_name": "Susan Coldiron", 
                    "phone": "941-623-9744"
                }, 
                "facility": {
                    "address": {
                        "city": "Port Charlotte", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33952"
                    }, 
                    "name": "Medsol Clinical Research Center"
                }, 
                "investigator": {
                    "last_name": "George Li, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bgepilepsy@outlook.com", 
                    "last_name": "Amber Chumley", 
                    "phone": "859-313-4273"
                }, 
                "contact_backup": {
                    "email": "bgepilepsy@outlook.com", 
                    "last_name": "Toufic Fakhoury, MD", 
                    "phone": "859.313.4273"
                }, 
                "facility": {
                    "address": {
                        "city": "Lexington", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40504"
                    }, 
                    "name": "Bluegrass Epilepsy Research, LLC"
                }, 
                "investigator": {
                    "last_name": "Toufic Fakhoury, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "barbera@epilepsydc.com", 
                    "last_name": "Arkady Barber", 
                    "phone": "301-530-9744"
                }, 
                "contact_backup": {
                    "last_name": "Lenka Goldman", 
                    "phone": "301-530-9744"
                }, 
                "facility": {
                    "address": {
                        "city": "Bethesda", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20817"
                    }, 
                    "name": "Mid-Atlantic Epilepsy Center"
                }, 
                "investigator": {
                    "last_name": "Pavel Klein, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kathy.sowell@mpls-clinic.com", 
                    "last_name": "Kathy Sowell, MA", 
                    "phone": "763-302-4135"
                }, 
                "contact_backup": {
                    "last_name": "Katrina Miller", 
                    "phone": "763-302-4135"
                }, 
                "facility": {
                    "address": {
                        "city": "Golden Valley", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55422"
                    }, 
                    "name": "Minneapolis Clinic of Neurology"
                }, 
                "investigator": {
                    "last_name": "Joanne Rogin, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "werosenfeld@msn.com", 
                    "last_name": "Patty Schaefer", 
                    "phone": "314-453-9300"
                }, 
                "facility": {
                    "address": {
                        "city": "Chesterfield", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63017"
                    }, 
                    "name": "The Comprehensive Epilepsy Care Center for Children and Adults"
                }, 
                "investigator": {
                    "last_name": "William Rosenfeld, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mmalik@epilepsygroup.com", 
                    "last_name": "Munazza Malik, MD", 
                    "phone": "201-343-6676", 
                    "phone_ext": "122"
                }, 
                "contact_backup": {
                    "last_name": "Evan Fertig, M.D.", 
                    "phone": "201-343-6676"
                }, 
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07601"
                    }, 
                    "name": "Northeast Regional Epilepsy Group"
                }, 
                "investigator": {
                    "last_name": "Evan Fertig, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kbyrnes@winthrop.org", 
                    "last_name": "Kim Brynes", 
                    "phone": "516-663-2815"
                }, 
                "facility": {
                    "address": {
                        "city": "Mineola", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11501"
                    }, 
                    "name": "Winthrop University Hospital"
                }, 
                "investigator": {
                    "last_name": "Shicong Ye, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "JKrec@SSandG.com", 
                    "last_name": "Jennifer Simpkins-Krec", 
                    "phone": "330-494-2097", 
                    "phone_ext": "138"
                }, 
                "contact_backup": {
                    "email": "WShaffer@SSandG.com", 
                    "last_name": "Wendy Shaffer", 
                    "phone": "330-494-2097", 
                    "phone_ext": "138"
                }, 
                "facility": {
                    "address": {
                        "city": "Canton", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44718"
                    }, 
                    "name": "Ohio Clinical Research Partners, LLC"
                }, 
                "investigator": {
                    "last_name": "Jennifer Drake, DO", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Stephanie.Scarberry@osumc.edu", 
                    "last_name": "Stephanie Scarberry, RN", 
                    "phone": "614-688-4678"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43221"
                    }, 
                    "name": "Ohio State University"
                }, 
                "investigator": {
                    "last_name": "Bassel Shneker, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "afreyman@lhsi.net", 
                    "last_name": "Aimee Freyman", 
                    "phone": "405-602-3928"
                }, 
                "contact_backup": {
                    "email": "pmorris@lhsi.net", 
                    "last_name": "Phyllis Fahrenbruch", 
                    "phone": "405-602-3939"
                }, 
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73112"
                    }, 
                    "name": "Lynn Health Institute"
                }, 
                "investigator": {
                    "last_name": "Mark Fisher, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jbrown@texasepilepsy.org", 
                    "last_name": "Joyce Brown", 
                    "phone": "972-707-8378"
                }, 
                "contact_backup": {
                    "email": "tsneed@texasepilepsy.org", 
                    "last_name": "Tawaika Sneed", 
                    "phone": "972-707-8378"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75251"
                    }, 
                    "name": "Texas Epilepsy Group"
                }, 
                "investigator": {
                    "last_name": "Jay Harvey, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cdburton@rainier-research.com", 
                    "last_name": "Carole Burton, RN", 
                    "phone": "425-251-1720"
                }, 
                "facility": {
                    "address": {
                        "city": "Renton", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98057"
                    }, 
                    "name": "Rainier Clinical Research Center, Inc."
                }, 
                "investigator": {
                    "last_name": "David Vossler, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Double Blind, Randomized, Placebo-Controlled Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults With Drug-Resistant Partial-Onset Seizures Followed by Long-term Open-Label Treatment", 
        "overall_contact": {
            "email": "jtsai@marinuspharma.com", 
            "last_name": "Julia Tsai, Ph.D.", 
            "phone": "203-315-5820"
        }, 
        "overall_official": {
            "affiliation": "Marinus Pharmaceuticals, Inc.", 
            "last_name": "Gail Farfel, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage change in seizure frequency per 28 days in the double blind period relative to baseline", 
            "safety_issue": "No", 
            "time_frame": "9 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01963208"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in seizure frequency per 28 days", 
                "safety_issue": "No", 
                "time_frame": "9 weeks and 52 weeks"
            }, 
            {
                "measure": "Proportion of responders experiencing a \u226550% reduction from baseline to the end of the period, in total partial seizure frequency per 28 days", 
                "safety_issue": "No", 
                "time_frame": "9 weeks and 52 weeks"
            }, 
            {
                "measure": "Proportion of seizure free subjects", 
                "safety_issue": "No", 
                "time_frame": "9 weeks and 52 weeks"
            }, 
            {
                "measure": "Clinical Global Impression of change", 
                "safety_issue": "Yes", 
                "time_frame": "9 weeks and 52 weeks"
            }, 
            {
                "measure": "Patient Global Impression of change", 
                "safety_issue": "Yes", 
                "time_frame": "9 weeks and 52 weeks"
            }, 
            {
                "measure": "Change in the number of seizure-free days", 
                "safety_issue": "No", 
                "time_frame": "9 weeks and 52 weeks"
            }
        ], 
        "source": "Marinus Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Marinus Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}